John Libbey Eurotext

Ketogenic diet for focal epilepsy with SPTAN1 encephalopathy Volume 24, issue 4, August 2022

Figures

  • Figure 1.
Authors
1 Japan Community Healthcare Organization Osaka Hospital, Osaka, Japan
2 Department of Pediatrics, Osaka University Graduate School of Medicine, Osaka, Japan
3 Epilepsy Center, Osaka University Hospital, Osaka, Japan
4 United Graduate School of Child Development, Osaka University Graduate School of Medicine, Osaka, Japan
5 Department of Pediatrics, Showa University School of Medicine, Tokyo, Japan
6 Department of Pediatrics, Yamagata University Faculty of Medicine, Yamagata-shi, Japan
7 Department of Pediatrics, Epilepsy Center Nishi-Niigata Chuo National Hospital, Niigata, Japan
8 Department of Human Genetics, Yokohama City University Graduate School of Medicine, Yokohama City, Japan
9 Department of Biochemistry, Hamamatsu University School of Medicine, Japan, Shizuoka, Japan
Correspondence:
Shin Nabatame
Department of Pediatrics, Osaka University Graduate School of Medicine, 2-2 Yamadaoka, Suita, Osaka 565-0871, Japan

SPTAN1 (non-erythrocytic alpha-spectrin-1) encephalopathy is a wide spectrum of neurodevelopmental disorders that includes epilepsy which is highly resistant to antiepileptic drugs [1]. There isnoeffectivetreatmentforfocalseizures following resolution of epileptic spasms byadrenocorticotropichormone(ACTH) or vigabatrin. In our regular epilepsy practice, the ketogenic diet (KD) is rarely adopted as an early treatment for epilepsy relative to drug therapy. Although the KD has successfully reduced [...]